The Chief Executive Officer of Avalo Therapeutics (AVTX) is Dr. Garry Neil, who has led the clinical-stage biotechnology enterprise. Bringing extensive pharmaceutical R&D and executive leadership experience from major global life science corporations—including Johnson & Johnson, AstraZeneca, and Merck—he oversees the company's strategic clinical pipeline development, corporate governance, and execution of pivotal trials for its immunology assets.